{
  "drugid": "RxNorm:1455099",
  "drugname": "vortioxetine",
  "guidelinename": "CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/",
  "guidelinepharmgkbids": [],
  "citations": [
    {
      "pmid": "37032427",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.",
      "authors": [
        "Bousman Chad A",
        "Stevenson James M",
        "Ramsey Laura B",
        "Sangkuhl Katrin",
        "Hicks J Kevin",
        "Strawn Jeffrey R",
        "Singh Ajeet B",
        "Ruaño Gualberto",
        "Mueller Daniel J",
        "Tsermpini Evangelia Eirini",
        "Brown Jacob T",
        "Bell Gillian C",
        "Leeder J Steven",
        "Gaedigk Andrea",
        "Scott Stuart A",
        "Klein Teri E",
        "Caudle Kelly E",
        "Bishop Jeffrey R"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2023
    }
  ],
  "recommendations": [
    {
      "implications": {
        "CYP2D6": "Greatly reduced metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate 50% of starting dose (e.g., 5 mg) and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.0"
      },
      "comments": "Drug-drug interactions, indication and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.25"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.5"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.75"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.75"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2D6": "Indeterminate"
      },
      "activityscore": {
        "CYP2D6": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "n/a"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.5"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.75"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.75"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "3.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "3.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "4.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "4.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.25"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.5"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.75"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.75"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥4.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥4.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥5.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥5.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥6.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥6.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.25"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.5"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.75"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.75"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.25"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "CYP2D6"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.25.0",
  "source": "CPIC"
}